In a clinical study in FGFR2-mutant or wild-type endometrial cancer patients treated with dovitinib, the RR in the FGFR2 mutant group was 5% (11% for all patients); only 1/22 FGFR2 mutant patients achieved a partial response (PR) [57]. Here, FGFR2 is linked to endometrial cancer.